2 assets in Lymphomatoid Granulomatosis

Therapeutic assets addressing Lymphomatoid Granulomatosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Lymphomatoid Granulomatosis	National Cancer Institute (NCI)	P2	CCC (53)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer Lymphomatoid Granulomatosis	National Cancer Institute (NCI)	P2	CC (44)